LLG 88Alternative Names: LLG88
Latest Information Update: 06 Aug 2004
At a glance
- Originator Unknown
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 06 Aug 2004 Discontinued - Preclinical for Alzheimer's disease in Italy (unspecified route)
- 11 Aug 2003 Preclinical trials in Alzheimer's disease in Italy (unspecified route)